摘要
目的:比较不同化疗方案用于小细胞食管癌的疗效和安全性。方法:回顾性分析58例小细胞食管癌患者资料,按化疗方案的不同分为A组(18例)、B组(26例)和C组(14例)。A组患者静脉滴注顺铂注射液75 mg/m^2,d_(1-3)+紫杉醇注射液175 mg/m^2,d_(1-3)。B组患者静脉滴注顺铂注射液30 mg/m^2,d_(1-3)+依托泊苷注射液100 mg/m^2,d_(1-3)。C组患者静脉滴注酒石酸长春瑞滨注射液25mg/m^2,d_(1-3)+注射用盐酸吉西他滨1 000 mg/m^2,d_(1-3)。3组均以21 d为1个周期,共治疗2个周期。比较3组患者的临床疗效及1、2、3年生存率及Ⅲ~Ⅳ度毒性反应(咳嗽、高热、咳痰、气促、乏力、胸痛、骨髓抑制、消化道反应)发生情况。结果:总有效率及1、2、3年生存率C组>B组>A组,Ⅲ~Ⅳ度咳嗽、高热、咳痰、气促、乏力、胸痛发生率C组<B组<A组,差异均有统计学意义(P<0.05);3组患者Ⅲ~Ⅳ度骨髓抑制、消化道反应发生率比较,差异均无统计学意义(P>0.05)。结论:长春瑞滨联合吉西他滨治疗小细胞食管癌疗效及1、2、3年生存率均显著高于顺铂联合紫杉醇或依托泊苷,且安全性优于顺铂联合紫杉醇或依托泊苷。
OBJECTIVE: To compare therapeutic efficacy and safety of different chemotherapy regimens in the treatment of small cell esophageal cancer. METHODS: In retrospective analysis, 58 patients with small cell esophageal cancer were divided into group A(18 cases),B(26 cases) and C(14 cases) according to chemotherapy regimens. Group A was given Cisplatin injection 75 mg/m^2 intravenously, d1-3^+Paclitaxel injection 175 mg/m^2, d1-3. Group B was given Cisplatin injection 30 mg/m^2 intravenously, d1-3+Et- oposide injection 100 mg/m^2, d1-3. Group C was given Vinorelbine tartrate injection 25 mg/m^2 intravenously, d1-3+Gemcitabine hydro- chloride for injection 1 000 mg/m^2,d1-3. A treatment course of 3 groups lasted for 21 d, and they all received 2 cycles of treatment. Clinical efficacies, 1, 2, 3-year survival rate and the incidence of III-IV degree toxic reaction (cough, fever, expectoration, short- ness of breath, fatigue, chest pain, bone marrow suppression, gastrointestinal reactions) were compared among 3 groups. RE- SULTS: Total response rate and 1, 2, 3-year survival rate were in descending order: group C〉group B〉group A; the incidence of HI-IV degree cough, fever, expectoration, shortness of breath, fatigue, chest pain were in ascending order: group C'〈group B〈group A, with statistical significance (P〈0.05). There was no statistical significance in the incidence of Ill-IV degree myelo- suppression and digestive tract reaction among 3 groups (P〉0.05). CONCLUSIONS: Therapeutic efficacy and 1,2,3-year survival rate of vinorelbine combined with gemcitabine are significantly higher than those of cisplatin combined with paclitaxel or etoposide with better safety.
出处
《中国药房》
CAS
北大核心
2017年第12期1623-1625,共3页
China Pharmacy
关键词
顺铂
紫杉醇
依托泊苷
长春瑞滨
吉西他滨
小细胞食管癌
疗效
安全性
Cisplatin
Paclitaxel
Etoposide
Vinorelbine
Gemcitabine
Small cell esophageal cancer
Therapeutic efficacy
Safety